Discontinuation report TAZORAC
| Report ID | 204561 |
| Drug Identification Number | 02230785 |
| Brand name | TAZORAC |
| Common or Proper name | Tazarotene cream |
| Company Name | ALLERGAN INC |
| Market Status | MARKETED |
| Active Ingredient(s) | TAZAROTENE |
| Strength(s) | 0.1% |
| Dosage form(s) | GEL |
| Route of administration | TOPICAL TOPICAL |
| Packaging size | 12 x 3.5g and 30 g |
| ATC code | D05AX |
| ATC description | ANTIPSORIATICS FOR TOPICAL USE |
| Reason for discontinuation | Business reasons |
| Anticipated discontinuation date | |
| Actual discontinuation date | 2023-09-30 |
| Remaining supply date | 2023-09-30 |
| Discontinuation status | To be discontinued |
| Discontinuation decision reversal | No |
| Information on remaining supply | |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Company contact information | Company contact information; Telephone number: 800-668-6424 Email address: MR-GENERAL_INQUIRY@allergan.com Website address: allergan.ca Postal address: 500-85 Enterprise Blvd, Markham, Ontario, L6G 0B5 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2023-09-15 | French | Compare |
| v1 | 2023-09-15 | English | Compare |
Showing 1 to 2 of 2